两大巨头接连‘踩坑’,为什么‘药王’也治不了阿尔茨海默症?

制药在线
Dec 02, 2025

2025年11月下旬,全球制药行业的目光被连续两起失败所吸引。11月24日,丹麦巨头诺和诺德宣布,其口服司美格鲁肽治疗早期阿尔茨海默症的两项关键III期临床试验(EVOKE和EVOKE+)未能达到延缓疾病进展的主要终点。短短几天后,强生公司紧随其后,宣布终止其抗tau蛋白抗体药物Posdinemab的II期临床试验,原因同样是未能显著改善患者临床症状。四天内,两家跨国药企在阿尔茨海默症(AD)这一...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10